Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.2838
-0.0132 (-4.44%)
At close: Aug 6, 2026, 4:00 PM EDT
0.2900
+0.0062 (2.18%)
Pre-market: Aug 7, 2026, 5:45 AM EDT

Vistagen Therapeutics Financials Overview

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
1.271.270.491.06-0.231.11
Revenue Growth
161.11%161.11%-54.32%--1.78%
Gross Profit
1.271.270.491.06-0.231.11
Operating Income
-72.13-72.13-55.97-33.02-59.27-47.78
Net Income
-69.69-69.69-51.42-29.36-59.24-48.71
Earnings Per Share
-1.83-1.83-1.67-1.52-8.51-7.38
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
45.445.480.48119.1716.6468.14
Total Debt
1.041.041.512.122.713.04
Net Cash (Debt)
44.3644.3678.97117.0513.9365.1
Net Cash Growth
-43.83%-43.83%-32.53%740.43%-78.61%-34.50%
Net Cash Per Share
1.171.172.566.052.009.86

Cash Flow & CapEx

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-66.44-66.44-42.1-25.81-49.72-45.26
Capital Expenditures
-0.15-0.15-0.19-0.06-0.21-0.2
Free Cash Flow
-66.59-66.59-42.29-25.87-49.93-45.46
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-5683.69%-5683.69%-11517.10%-3103.48%26109.30%-4308.68%
Pretax Margin
-5490.78%-5490.78%-10578.40%-2759.21%26097.80%-4306.88%
Profit Margin
-5491.33%-5491.33%-10579.80%-2759.59%26095.20%-4306.57%
FCF Margin
-5247.20%-5247.20%-8701.23%-2431.77%21994.70%-4099.28%

Valuation

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PS Ratio
9.1817.84149.16134.11-115.95230.96